The LEVANT I (Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis) Trial for Femoropopliteal Revascularization
نویسندگان
چکیده
From the *Center of Vascular Medicine, Heart Center Leipzig/Park Hospital, Leipzig, Germany; yCenter for Diagnostic Radiology and Minimally Invasive Therapy, Jewish Hospital, Berlin, Germany; zDepartment of Interventional Angiology, Herz-Zentrum, Bad Krozingen, Germany; xCardiovascular Center, Hamburg University Cardiovascular Center, Hamburg, Germany; kClinic for Radiology and Nuclear Medicine, University of Magdeburg, Magdeburg, Germany; {Flanders Medical Research Program, JACC:CARDIOVASCULAR INTERVENTIONSCME
منابع مشابه
Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial.
BACKGROUND The success of percutaneous intervention in peripheral arterial disease is limited by restenosis. The aim of the present pilot study was to evaluate a novel method of local drug delivery. METHODS AND RESULTS This randomized multicenter study with blinded reading enrolled 87 patients in Rutherford class 1 to 4 with occlusion or hemodynamically relevant stenosis, restenosis, or in-st...
متن کاملPaclitaxel-coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: a meta-analysis of randomized trials.
BACKGROUND In disease of the femoropopliteal artery, paclitaxel-coated balloon (PCB) therapy improved angiographic outcomes as compared with uncoated balloon (UCB) angioplasty. Nevertheless, it remains uncertain whether PCB may reduce the need for reintervention. METHODS AND RESULTS We searched Medline, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), scientific session a...
متن کاملLocal delivery of paclitaxel to inhibit restenosis during angioplasty of the leg.
BACKGROUND Drug-eluting stents reduce restenosis in coronary arteries, but clinical trials have failed to prove their efficacy in peripheral arteries. We investigated the use of paclitaxel-coated angioplasty balloons and paclitaxel dissolved in the angiographic contrast medium during angioplasty of the leg. METHODS In a small, multicenter trial, we randomly assigned 154 patients with stenosis...
متن کاملTreatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents.
OBJECTIVES This study sought to evaluate the outcomes of drug-eluting stent treatment for femoropopliteal in-stent restenosis (ISR). BACKGROUND ISR after femoropopliteal interventions is an increasing problem. Although the role of drug-eluting stents in the treatment of coronary ISR is well defined, no published studies have examined drug-eluting stents in the treatment of femoropopliteal ISR...
متن کاملDurable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
BACKGROUND This randomized controlled trial evaluated clinical durability of Zilver PTX, a paclitaxel-coated drug-eluting stent (DES), for femoropopliteal artery lesions. Outcomes compare primary DES versus percutaneous transluminal angioplasty (PTA), overall DES (primary and provisional) versus standard care (PTA and provisional Zilver bare metal stent [BMS]), and provisional DES versus provis...
متن کامل